Glycomedicine: How Glycans Are Reshaping Drug Discovery, Vaccines and Personalised Treatment

Glycomedicine is the application of glycobiology — the science of complex sugars called glycans — to the development of drugs, vaccines, and personalised treatment strategies. Glycans coat every cell in the human body and regulate inflammation, immune function, and cellular communication. Because they sit at the interface between genetics and environment, glycans offer something neither DNA nor standard blood biomarkers can: a real-time readout of how biology is actually functioning, not just what it is genetically programmed to do.

This article answers the questions most often asked about glycan therapeutics, from the foundational science to the clinical implications of measuring glycan biology in practice.

Not yet familiar with what glycans are and how they shape biological age? Start with the essentials: Glycans: The Sugars That Reveal Your Biological Age and Immune Health.

How are glycans different from genes, and why does that matter for personalised medicine?

Glycans change the function of a molecule in real time without requiring any change to the underlying gene, making them the most dynamic layer of human biology available for measurement and intervention. Prof. Gordan Lauc, CSO and Co-Founder of GlycanAge, has written about glycans as representing a third revolutionary layer in evolution — the post-translational system that sits above DNA and proteins. DNA is transcribed into RNA, translated into proteins, and then those proteins are modified by the addition of glycans, complex oligosaccharides that regulate protein function post-translationally. This means glycans add a layer of biological response that doesn't require a new generation or a change in gene expression; the body can alter molecular function in real time by adjusting glycan structures.

For personalised medicine, this distinction is significant. Genetic risk is fixed. Whatever your DNA says, it says regardless of what you do. Glycans, by contrast, integrate genetic predisposition with past lifestyle, hormonal status, stress, and environmental exposures into a single measurable signal. As Prof. Lauc describes it, glycans capture both the genetic risk encoded in a person's biology and the cumulative effects of their lifestyle over the preceding decades, integrating where someone started with what they have done to themselves since.

Why are glycans considered promising biomarkers in multiomics research?

Glycans are considered intermediate phenotypes, positioned between rapidly fluctuating metabolites and static genes, which makes them uniquely informative biomarkers in a multiomics framework. Standard clinical biomarkers such as glucose, enzymes, and metabolites change hour to hour; genes do not change at all. Glycans occupy the space between these extremes, integrating genetic, epigenetic, and environmental factors into a stable but modifiable signal.

"We are missing some kind of intermediate phenotypes between these day-to-day altering molecules and genes which do not change, and these are the glycans."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

In a multiomics context, this positions glycans as the connective layer that gives other omics data biological context. A genomics result tells you what could happen; a glycan measurement tells you what is happening now.

How do glycans regulate immune function and inflammation?

Glycans on immunoglobulin G (IgG) antibodies (the most abundant antibody in human blood) directly determine whether the immune response is pro-inflammatory or anti-inflammatory. As we age, the balance shifts: pro-inflammatory glycan structures accumulate while anti-inflammatory structures decline, a process that drives the chronic, low-grade inflammation now recognised as a central mechanism of biological aging, often called inflammaging.

This shift is not uniform. Large population studies show a pronounced gender difference: women tend to maintain a more favorable glycan profile than men up to a certain age, after which the trajectory changes sharply, particularly around perimenopause. Cancer biology illustrates the stakes from another angle: cancer cells have learned to coat themselves in "healthy-looking" glycans to evade immune surveillance, exploiting the same glycan-mediated communication system that governs normal immune function. Understanding and modulating this system is the basis of glycan-targeted therapeutic development.

Can glycan measurements validate whether a treatment or lifestyle intervention is actually working?

GlycanAge is the most accurate at-home biological age test measuring active chronic inflammation through glycan biomarkers, and it responds to interventions within 3–6 months, which is fast enough to be clinically actionable. Prof. Lauc has tracked his own GlycanAge for nearly a decade, observing how the number moves directly in response to his choices, improving during healthier periods and rising during more difficult ones.

"If I change into a healthier lifestyle it actually goes down — I can say I'm saving healthy years of my life. And then in a difficult period it can accelerate."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

For those managing complex health protocols, an objective biomarker that responds to lifestyle and clinical interventions within months addresses a persistent gap: most protocols, such as supplements, hormone therapy, lifestyle changes, lack a personalised, measurable indicator of biological effect. GlycanAge provides exactly that. Objective measurement that visibly responds to intervention is also a documented driver of patient adherence. It is evidence that the feedback loop itself changes behaviour.

What role will glycans play in the future of drug discovery and diagnostics?

Glycans will become the most important prognostic biomarkers in medicine, telling clinicians how far along the path from health to disease a patient has already traveled. Prof. Lauc points to their integrative nature as the reason glycans will play a central role in the future of medicine.

"Glycans will be very important in this field because they are integrating genetic, epigenetic, and environmental factors."

— Prof. Gordan Lauc, Chief Scientific Officer, GlycanAge; Professor of Biochemistry and Molecular Biology, University of Zagreb

At present, glycans are not yet routine diagnostic biomarkers (significant validation steps remain) but the trajectory is clear.

In drug discovery, the implications are substantial. Because glycans mediate cell-to-cell communication and determine protein functionality (proteins without their glycan structures simply do not function correctly) they are both therapeutic targets and response biomarkers. Research suggests the endothelial glycocalyx (the glycan coating of arterial walls) plays a significant role in cardiovascular health: when it erodes, arterial integrity declines. As Prof. Lauc notes, one specific glycan structure has been identified as among the strongest predictors of cardiovascular events, including heart attack and stroke. As glycan measurement becomes more accessible and the evidence base grows, glycan-targeted interventions and glycan-based patient stratification will move from research settings into clinical practice.

How does GlycanAge fit into a multiomics or functional medicine workflow?

GlycanAge measures 29 glycan structures on IgG antibodies from a simple finger-prick blood sample, returning a biological age and a set of glycan indexes that reveal where chronic inflammation is driving accelerated immune aging. Within a multiomics or functional medicine workflow, it fills the gap that genomics, epigenetics, and standard blood panels leave open: a stable, modifiable, inflammation-specific signal that responds to interventions on a clinically relevant timescale.

Practitioners use GlycanAge to baseline patients before initiating interventions, monitor biological response at 3–6 months, and adjust protocols based on objective data rather than symptom reporting alone. The test is built on over 30 years of glycobiology research, more than 350 published scientific papers, and analysis of over 300,000 glycan samples, giving it a depth of population reference data unique to IgG glycan-based biological age testing. For any clinician running a comprehensive longevity or functional medicine panel, GlycanAge is the inflammatory and immune-aging layer that standard blood work does not capture.

If you are looking to integrate glycan biomarker testing into your clinical workflow, GlycanAge's Healthcare Providers programme offers validated protocols, clinical education, and a retest cadence designed to demonstrate intervention effectiveness to your patients.

Explore GlycanAge for Healthcare Providers →

External Sources

• https://academic.oup.com/biomedgerontology/article/69/7/779/662651 — Krištić J, Vučković F, Menni C, et al. Glycans Are a Novel Biomarker of Chronological and Biological Ages. The Journals of Gerontology: Series A, 2014;69(7):779–789.

• https://www.ncbi.nlm.nih.gov/books/NBK579918/ — Varki A, Cummings RD, Esko JD, et al., eds. Essentials of Glycobiology, 4th edition. Cold Spring Harbor Laboratory Press; 2022. NCBI Bookshelf.

• https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.123.323623 — Hoshi RA, Plavša B, Liu Y, et al. N-Glycosylation Profiles of Immunoglobulin G and Future Cardiovascular Events. Circulation Research, 2024;134:e3–e14.